Related Resources for this page:

DLBCL

Diffuse Large B-cell Lymphoma (DLBCL)

Disease Information

Genentech BioOncology is dedicated to advancing the science of DLBCL therapy through comprehensive research programs and education. DLBCL is a cancer of B-lymphocytes in the lymphatic system.1 Molecular, pathogenic, and clinical features distinguish 2 subtypes of DLBCL2:

  • Germinal center B-cell–like DLBCL, originating in germinal center B cells, has a 60% 5-year survival rate2
  • Activated B-cell–like DLBCL, originating in the postgerminal center B cell, has a 35% 5-year survival rate2

DLBCL Demographic Statistics

  • The Surveillance, Epidemiology and End Results (SEER) Program found 22,390 cases of DLBCL not otherwise specified3
  • DLBCL accounts for about 1 of every 3 cases of non-Hodgkin’s lymphoma1
  • An estimated 10,000 deaths result from DLBCL annually in the United States4
  • DLBCL is usually aggressive, marked by rapidly growing tumors in lymph nodes, spleen, liver, bone marrow, or other organs5

DLBCL Epidemiology

  • DLBCL occurs mostly in older people (average age is mid-60s).1 Immunocompromise (eg, due to HIV infection) is another risk factor1
  • The 5-year survival rate for DLBCL is 50.4%3

The symptoms of DLBCL include rapidly growing tumors in the lymph nodes, spleen, liver, bone marrow, or other organs.5 Other symptoms include fever, night sweats, and weight loss.5

Other links to DLBCL disease information

These links give a sampling of other sites offering information on DLBCL disease, which you may find useful in your practice.

Unless otherwise indicated, Genentech, Inc. is neither affiliated with nor endorses any of the organizations listed.

References:
1.
American Cancer Society. Non-Hodgkin lymphoma. www.cancer.org/acs/groups/cid/documents/webcontent/003126-pdf.pdf. Accessed April 14, 2011.
2.
Lossos IS. Molecular pathogenesis of diffuse large B-cell lymphoma. J Clin Oncol. 2005;23:6351-6357. PMID: 16155019
3.
Clarke C, O’Malley C. Non-Hodgkin lymphoma. In SEER Survival Monograph. National Cancer Institute. www.seer.cancer.gov/publications/survival/surv_nonhodgkin.pdf. Accessed April 14, 2011.
4.
US Department of Health and Human Services. National Cancer Institute. Sending the right signal. http://home.ccr.cancer.gov/inthejournals/staudt.asp. Accessed April, 22, 2011.
5.
US Department of Health and Human Services. National Cancer Institute. What you need to know about™ non-Hodgkin lymphoma. NIH Publication No. 07-1567.